Study of Safety and Efficacy of OncoVEXGM-CSF With Cisplatin for Treatment of Locally Advanced Head and Neck Cancer

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT01161498
• Date of registration: 12/07/2010
• Primary sponsor: BioVex Limited
• Public title: Study of Safety and Efficacy of OncoVEXGM-CSF With Cisplatin for Treatment of Locally Advanced Head and Neck Cancer
• Scientific title: A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEXGM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck
• Date of first enrolment: December 2010
• Target sample size: 528
• Recruitment status: Terminated
• URL: http://clinicaltrials.gov/show/NCT01161498
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Countries of recruitment

United Kingdom, United States

Contacts

• Name: Kevin Harrington, MD
• Affiliation: Royal Marsden, UK

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Male or female = 18 years

2. ECOG Performance Status = 1

3. Histological evidence (from the primary lesion and/or lymph nodes) of squamous cell
carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx

4. Stage III or IV disease (T2N2-3M0, T3-4N1-3M0)

5. No evidence of distant metastases by CT or PET/CT scan

6. Life expectancy > 4 months

7. Neutrophil count = 2,000/mm^3

8. Platelet count = 100,000/mm^3

9. Hemoglobin = 10 g/dL

10. Bilirubin = 1.5 times ULN

11. AST and ALT = 2.5 times ULN

12. Alkaline phosphatase = 2.5 times ULN

13. Creatinine clearance = 60 mL/min

14. Female patients of child-bearing potential (i.e. not surgically sterile, or not
having spontaneous amenorrhea for at least 12 months) must agree to use an effective
form of contraception during the treatment phase of the study.

15. Male patients must agree to use a condom with spermicide or their female partner must
use an effective method of birth control.

16. Provide written informed consent in accordance with all applicable regulations and
follow the study procedures. Patients must be capable of understanding the
investigational nature, potential risks and benefits of the study.

Exclusion Criteria:

1. Prior treatment for locally advanced SCCHN (NO prior surgery for SCCHN except nodal
sampling or biopsy for study disease).

2. Patients with T1-2N1 or T1N2-3.

3. Pre-existing peripheral neuropathy = Grade 2 (motor or sensory).

4. Weight loss > 20% of body weight within 3 months of screening (unless purposeful).

5. Surgery = 28 days before randomization with the exception of feeding tube placement,
dental extractions, central venous catheter placement, biopsies and nodal sampling.

6. Cancer of the nasopharynx, sinus, salivary gland or skin.

7. Previous radical RT to the head and neck region, excluding superficial RT for a
non-melanomatous skin cancer.

8. Prior cancers, except: those diagnosed > 5 years ago with no evidence of disease
recurrence and clinical expectation of recurrence of less than 5%; or successfully
treated non-melanoma skin cancer; or carcinoma in situ of the cervix.

9. Significant intercurrent illness that will interfere with the chemotherapy or
radiation therapy such as HIV infection, cardiac failure, pulmonary compromise
(chronic obstructive pulmonary disease, pneumonia or respiratory decompensation)
resulting in hospitalization within 12 months of screening, or active infection.

10. Any significant cardiac disease (e.g., New York Heart Association (NYHA) Class 3 or
4; myocardial infarction within the past 6 months; unstable angina; coronary
angioplasty or coronary artery bypass graft (CABG) within the past 6 months; or
uncontrolled atrial or ventricular cardiac arrhythmias..

11. High risk for poor compliance with therapy or follow up as assessed by the
investigator.

12. Active herpes labialis, other lesions due to HSV1 or dermatoses involving or within
50 cm of the lesions to be injected; active HSV1 lesions must have resolved before
OncoVEXGM-CSF is injected.

13. Prior systemic chemotherapy for any type of cancer.

14. Patients for whom radiation therapy is contraindicated.

15. Pregnant or breast-feeding female. Confirmation that women of child-bearing potential
are not pregnant. A negative serum ß- human chorionic gonadotropin (ß-hCG) pregnancy
test result must be obtained during the screening period.

16. Currently enrolled and receiving an investigational agent in a clinical research
study or received an investigational agent for any reason within 4 weeks prior to
screening.

17. Require intermittent or chronic treatment with an anti-herpetic drug (e.g.,
acyclovir), other than intermittent topical use.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Head and Neck Cancer

SQUAMOUS CELL CARCINOMA

Intervention(s)

Biological: OncoVEX^GM-CSF

Other: Radiation/cisplatin

Primary Outcome(s)

To demonstrate a statistically significant increase in 2-year event free survival for patients treated with OncoVEX^GM-CSF as compared to patients treated with chemoradiation alone. [Time Frame: 2 years]

Secondary ID(s)

006/09

Source(s) of Monetary Support

Please refer to primary and secondary sponsors